GSK to start three-year plan to save cash, takes £1.33B hit on cough trial failure

EarningsnegativeNegative

AI Analysis

Summary

GSK announced a three-year restructuring program to reduce costs and streamline operations, taking a £1.33B charge related to a failed cough treatment trial in its Q2 earnings report.

Clinical Trial Data

Primary Endpoint

Not Met

Outcome Details

Cough trial failure resulted in £1.33B charge

Importance:6/10

Sentiment:

-0.70

restructuringcost-cuttingtrial failurewrite-downearnings

Related Companies

$GSK

Read the original article

Published by Endpoints News on July 28, 2026 11:35 AM

Read Original